Skip to content
Screener

Reported November 12, 2026 · Before market open

EPS-$0.48Beat by $0.09
EPS estimate-$0.57
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
Imran Alibhai

Next report

Date not yet announced

FAQ

When did Tvardi Therapeutics report Q3 2026 earnings?
Tvardi Therapeutics (TVRD) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Tvardi Therapeutics's Q3 2026 revenue and EPS?
Tvardi Therapeutics reported eps of $-0.48 for Q3 2026.
Did Tvardi Therapeutics beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.57 by $0.09.
How did Tvardi Therapeutics's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 18.6% from $-0.59.
Where can I find Tvardi Therapeutics's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-126507) and the 10-Q periodic report (0001104659-26-126508) directly on SEC EDGAR. The filing index links above go to sec.gov.